Qiagen NV Total Assets
Qiagen NV total assets. Based on the latest financial reports, Qiagen NV (QGEN) holds total assets worth $5.78 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see QGEN stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Qiagen NV (1995–2025)
Total assets of Qiagen NV from 1995 to 2025. This chart illustrates how Qiagen NV's total assets have evolved over time, based on quarterly financial data. See current stock price of Qiagen NV for real-time trading data and today's change.
Qiagen NV - Asset Composition Analysis
Qiagen NV Total Assets Breakdown (December 2025)
Qiagen NV total assets breakdown as of December 2025. Qiagen NV's total assets of $5.78 Billion consist of 31.7% current assets and 68.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $402.61 Million | 6.4% |
| Inventory | $301.89 Million | 4.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $386.43 Million | 6.1% |
| Goodwill | $2.70 Billion | 42.9% |
Asset Composition Trend (1995–2025)
This chart illustrates how Qiagen NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Qiagen NV to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qiagen NV's current assets represent 31.7% of total assets in 2025, a decrease from 66.0% in 1995.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2025, down from 20.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is goodwill at 42.9% of total assets.
Qiagen NV Competitors by Total Assets
Key competitors of Qiagen NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.59 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA
|
India | Rs15.07 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Qiagen NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.21 | 3.37 | 3.58 |
| Quick Ratio | 2.57 | 2.83 | 2.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.06 Billion | $1.23 Billion | $1.30 Billion |
Qiagen NV - Advanced Valuation Insights
This section examines the relationship between Qiagen NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.34 |
| Latest Market Cap to Assets Ratio | 1.24 |
| Asset Growth Rate (YoY) | 10.7% |
| Total Assets | $6.30 Billion |
| Market Capitalization | $7.79 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Qiagen NV's assets above their book value (1.24x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Qiagen NV's assets grew by 10.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Qiagen NV (1995–2025)
The table below shows the annual total assets of Qiagen NV from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.30 Billion | +10.66% |
| 2024-12-31 | $5.69 Billion | -6.96% |
| 2023-12-31 | $6.12 Billion | -2.74% |
| 2022-12-31 | $6.29 Billion | +2.29% |
| 2021-12-31 | $6.15 Billion | +4.72% |
| 2020-12-31 | $5.87 Billion | +12.11% |
| 2019-12-31 | $5.24 Billion | -8.92% |
| 2018-12-31 | $5.75 Billion | +14.09% |
| 2017-12-31 | $5.04 Billion | +16.95% |
| 2016-12-31 | $4.31 Billion | +2.83% |
| 2015-12-31 | $4.19 Billion | -5.94% |
| 2014-12-31 | $4.45 Billion | +8.95% |
| 2013-12-31 | $4.09 Billion | -0.91% |
| 2012-12-31 | $4.13 Billion | +9.84% |
| 2011-12-31 | $3.76 Billion | -4.03% |
| 2010-12-31 | $3.91 Billion | +3.10% |
| 2009-12-31 | $3.80 Billion | +31.58% |
| 2008-12-31 | $2.89 Billion | +3.97% |
| 2007-12-31 | $2.78 Billion | +128.97% |
| 2006-12-31 | $1.21 Billion | +58.37% |
| 2005-12-31 | $765.30 Million | +7.09% |
| 2004-12-31 | $714.60 Million | +29.47% |
| 2003-12-31 | $551.93 Million | +21.43% |
| 2002-12-31 | $454.51 Million | +27.33% |
| 2001-12-31 | $356.97 Million | +55.03% |
| 2000-12-31 | $230.26 Million | +55.46% |
| 1999-12-31 | $148.12 Million | +38.82% |
| 1998-12-31 | $106.70 Million | +35.23% |
| 1997-12-31 | $78.90 Million | +19.18% |
| 1996-12-31 | $66.20 Million | +152.67% |
| 1995-12-31 | $26.20 Million | -- |
About Qiagen NV
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technol… Read more